Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases

By sjmartinez • December 25, 2024

Aringer M, Distler O, Hoffmann-Vold AM, Kuwana M, Prosch H, Volkmann ER. Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases. RMD Open. 2024 Dec 23;10(4):e004704. doi: 10.1136/rmdopen-2024-004704. PMID: 39719300.

Tags: Autoimmune Diseases, Publications, Pulmonary fibrosis, Rheumatology, Therapeutics

Outcomes of Early Sodium-Glucose Cotransporter 2 Inhibitor Use in Takotsubo Syndrome: Insights from a Multicenter Real-World Cohort Study

Taha A, Mondal A, Sandhyavenu H, Atti L, Alhajji M, Thangjui S, Shaik BF, Thyagaturu H, Caccamo M, Fonarow GC, Balla S. Outcomes of Early[...]

Comparative Effectiveness of Single Versus Bilateral Lung Transplantation in Dually Listed Recipients: A National Target Trial

Sakowitz S, Bakhtiyar SS, Sanaiha Y, Sayah DM, Belperio JA, Bremner RM, Benharash P. Comparative Effectiveness of Single Versus Bilateral Lung Transplantation in Dually Listed[...]

Quality of hospital medicine care in Veterans Affairs hospitals versus non-Veterans Affairs hospitals: A systematic review of comparative studies

Shekelle PG, Burke RE, Apaydin EA, Begashaw MM, Wray CM. Quality of hospital medicine care in Veterans Affairs hospitals versus non-Veterans Affairs hospitals: A systematic[...]